Data / Form D filings / AltrixBio, Inc.
AltrixBio, Inc.: Form D filings
AltrixBio, Inc., a pharmaceuticals company in Lowell, MA, filed 3 Form D notices with the SEC in 2025. The latest, on June 16, 2025, reports $1.2 million sold of a $10 million offering to 20 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 110 Canal Street, 4th Floor, Lowell, MA, 01852
- Phone
- (302) 658-7581
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 504, Rule 506(c), Securities Act section 4(a)(5)
- SEC identifier (CIK)
- 2040517
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | New notice | $10,000,000 | $1,150,015 | $8,849,985 | 20 | Apr 30, 2025 | sec.gov |
| Jun 13, 2025 | Amendment | $6,632,847 | $6,632,847 | 50 | Mar 8, 2019 | sec.gov | |
| Jun 13, 2025 | New notice | $10,000,000 | $1,150,015 | $8,849,985 | 20 | Mar 18, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John Brooks | Director | |
| Jeffrey Karp | Director | |
| Ali Tavakkoli | Director | |
| Nancy Briefs | Executive Officer, Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Jun 16, 2025 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what AltrixBio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.